Susan Swabey - Smith Nephew Company Secretary
| SNNUF Stock | USD 12.39 0.31 2.57% |
Executive
Ms. Susan Swabey is Company Secretary of Smith Nephew PLC. She joined Smith Nephew in May 2009 as Company Secretary with responsibility for Board support and corporate governance, employee and executive share plans and subsidiary governance. In 2016, she also assumed responsibility for leading the groups risk management programme. She is based in Watford. Career and experience Susan has over 30 years experience as a Company Secretary in a wide range of companies including Prudential plc, Amersham plc and RMC Group plc. Her work has covered board support, corporate governance, remuneration, corporate transactions, group risk management, share registration, listing obligations, corporate social responsibility, pensions, insurance and employee and executive share plans. Susan holds an MA from Corporationrations Christi College Oxford in Literae Humaniores and is a Fellow of the Institution of Chartered Secretaries The Governance Institute. She is also Chair of ShareGift, the share donation charity, a member of the Financial Reporting Council Lab Steering Group and a frequent speaker on corporate governance and related matters. since 2009.
| Age | 56 |
| Tenure | 15 years |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Webb | LivaNova PLC | N/A | |
| Robert JD | Paragon 28 | 56 | |
| Jay Katz | Glaukos Corp | N/A | |
| Bryan Olin | LivaNova PLC | 57 | |
| Isabelle Billet | Axogen Inc | 62 | |
| Jan Metzdorff | Sonova Holding AG | 60 | |
| Daniel Esq | CONMED | 60 | |
| Demetrio Mauro | LivaNova PLC | N/A | |
| Tram Bui | Orthopediatrics Corp | N/A | |
| Brent Lalomia | CONMED | 49 | |
| Badri Amurthur | LivaNova PLC | N/A | |
| Doris Quackenbush | Axogen Inc | N/A | |
| Trui Hebbelinck | LivaNova PLC | 52 | |
| Jonathan Friedman | Paragon 28 | 53 | |
| Chris Calcaterra | Glaukos Corp | 64 | |
| Ivica MD | Axogen Inc | N/A | |
| David Hansen | Axogen Inc | 57 | |
| Maria Martinez | Axogen Inc | 56 | |
| Harold Tamayo | Axogen Inc | N/A | |
| Brandon Kraatz | Paragon 28 | N/A | |
| Andrew Senn | Integer Holdings Corp | 42 | |
Management Performance
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namal Nawana, CEO, Executive Director | ||
| Michael Friedman, Non-Executive Independent Director | ||
| Diogo MoreiraRato, President - Europe and Canada | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Director | ||
| Deepak Nath, CEO Director | ||
| Matthew Stober, President - Global Operations | ||
| Marc Owen, Non-Executive Director | ||
| AnneFrancoise Nesmes, CFO Director | ||
| Helen Barraclough, Company Counsel | ||
| Rodrigo Bianchi, President IRAMEA | ||
| Brian Larcombe, Senior Independent Non-Executive Director | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, Sports Orthopaedics | ||
| Gunthorp Oie, IR Contact Officer | ||
| Roland Diggelmann, Non-Executive Director | ||
| Helen Maye, Chief Human Resources Officer | ||
| Vinita Bali, Non-Executive Director | ||
| Simon Fraser, President - Advanced Wound Management | ||
| Massimiliano Colella, President Europe - Middle East and Africa | ||
| Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
| Graham Baker, CFO, Executive Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, VP Communications | ||
| Cyrille Petit, Chief Corporate Development Officer | ||
| Julie Brown, CFO, Director and Member of Disclosures Committee | ||
| Glenn Warner, President - Advanced Wound Management | ||
| Robin Freestone, Non-Executive Director | ||
| Paul Connolly, Pres Operations | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Director | ||
| Mark Gladwell, President - Global Operations | ||
| Andrew Swift, VP Relations | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Michael Frazzette, President - Advanced Surgical Devices | ||
| Joseph Papa, Non-Executive Independent Director | ||
| Ingeborg Oie, VP, Investor Relations | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Gordon Howe, President of Global Operations | ||
| John Campo, Chief Legal Officer | ||
| Brad Cannon, President Europe and Canada | ||
| Ian Barlow, Non-Executive Independent Director | ||
| Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 14.08 B | |||
| Shares Outstanding | 873.35 M | |||
| Shares Owned By Insiders | 0.17 % | |||
| Shares Owned By Institutions | 52.60 % | |||
| Price To Earning | 23.41 X | |||
| Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |